Shareprice
14 May 2025

About

FluoGuide A/S is a clinical stage biotechnology company focused on developing drugs for maximizing surgical outcomes by making cancer fluorescent.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Board of directors

Peter Mørch Eriksen - Chairman of the board FluoGuide

Peter Mørch Eriksen

Chairman of the board

Peter has more than 20 years of experience in the medtech/life science sectors, both in Denmark and internationally. He is CEO at BioPorto A/S. His extensive background includes key positions such as Vice President of Medtronic in the US and Denmark. These roles have endowed Peter with a wealth of knowledge in driving growth, executing restructuring, and securing funding in technologically advanced and complex organizations. Peter’s professional foundation is in accounting, complemented by various management courses. He chairs the board of Monsenso A/S, Chairman in AptaShape ApS and Director of PMEconsult ApS. Additionally, he contributes his expertise to the Medical Device and Diagnostics Advisory Committee of Cincinnati Children’s Hospital Medical Center in Ohio, US.

Born in 1960. Chairman of the board since 2021

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of  FluoGuide shares 115,669 and 87,500 warrants (Partly owned via PME Holding ApS)

Mats Thorèn - Vice chairman of the board FluoGuide

Mats Thorèn

Vice chairman of the board

Mats brings 25 years of financial market experience, specializing in healthcare through roles in equity analysis and corporate finance. He has spent 19 years as a Healthcare investment expert, working with firms like Nalka Life Science AB and MedCap AB, and now leads Vixco Capital. Mats holds board positions at Xbrane BioPharma AB, Arcoma AB, Herantis Pharma Oy, BioPorto A/S and C-Rad AB with past board roles at Duocort AB, Cellartis AB, and others. His educational background includes Economics, focusing on Accounting and Financial Economics, and medical studies at the Karolinska Institute in Stockholm.

Born in 1971. Board member since 2021

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 741 and 0 warrants

Andreas Kjaer - Member of the board FluoGuide

Andreas Kjaer

Member of the board

Andreas is an MD, PhD, DMSc, and professor at the University of Copenhagen as well as chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET and PET/MRI in cancer and cardiovascular disease and his achievements include development of several new tracers that have reached first-in-humans clinical use. He is the holder of an ERC Advanced Grant, has published 700 peer-review articles, and has received multiple prestigious scientific awards throughout the years. Andreas also holds an MBA from Copenhagen Business School.

Born in  1963. Board member since 2018.

Dependent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares  2,126,107 (owned via Life Science Aps) and privately 121,400 warrants .

 

Michael Engsig - Member of the board FluoGuide

Michael Engsig

Member of the board

Michael has extensive experience within the pharmaceutical industry with 20+ years of experience in both foreign capital markets and publicly listed companies. This includes a successful track record in general management, R&D, and commercial functions. Since 2019 Michael has been CEO at Nykode Therapeutics, Norway. Michael holds a M.Sc. in chemistry with a specialization in biotechnology from the Technical University of Denmark (DTU) and a graduate diploma in Business Administration (HD) from Copenhagen Business School (CBS).

Born in 1972. Board member since 2023

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 0 and 7,500 warrants

Donna Haire - Member of the board FluoGuide

Donna Haire

Member of the board

Donna is CEO of The Eriah Group, Inc., specializing in global regulatory, quality, clinical, and medical affairs consulting for drugs, biologics, medical devices/in vitro diagnostics, and combination products. With over 30 years in the healthcare, pharmaceutical, and medical device industries, she has extensive experience in regulatory, quality, clinical affairs, operations, business development, and R&D. Donna is currently a Board Member at Sedana Medical AB. She has served in executive roles at On Target Laboratories, Bayer, AngioDynamics, Philips Healthcare, and Medtronic. Donna was also an Adjunct Professor at the University of Akron School of Law, an AdvaMed Technical and Regulatory Board Committee Member, and a U.S. regulatory expert for international trade negotiations. She is a keynote speaker and panelist at global regulatory and compliance events.

Donna holds an M.S. in Biology from Cleveland State University and a B.S. in Biology from The University of Akron.

Board member since 2024

Independent in relation to both the Company and executive management as well as larger shareholders.

Number of FluoGuide shares 0 and 7,500 warrants